Skip to main content
🧬Peptide Protocol Wiki

5-Amino-1MQ: Risks & Legal Status

Important safety information, risks, and regulatory status

Reviewed byDr. Research Team(MD (composite credential representing medical review team), PhD in Pharmacology)
📅Updated February 18, 2026
Unverified

📌TL;DR

  • 4 risk categories identified
  • 0 high-severity risks
  • Legal status varies by country (2 countries listed)

Risk Assessment

No Human Clinical Data

The most fundamental risk of 5-Amino-1MQ use is the complete absence of human clinical trial data. No human pharmacokinetics, efficacy, safety, or dose-response data has been published. All evidence derives from mouse and cell culture studies.

Oral Bioavailability Unknown

Published animal studies used subcutaneous injection. Commercial products are oral capsules. Oral bioavailability has not been characterized, meaning the actual amount reaching target tissues via oral administration is unknown.

Long-term NNMT Inhibition Effects Unknown

NNMT plays roles in methylation balance, polyamine metabolism, and cellular homeostasis. Chronic inhibition could have unpredictable effects on epigenetics, cancer risk, and metabolic function that have not been evaluated.

Product Quality and Purity

As a research chemical without pharmaceutical regulation, commercial 5-Amino-1MQ products vary in quality, purity, and actual content. No standardized manufacturing processes or quality control requirements exist.

Risk assessment matrix for 5-Amino-1MQ
Visual risk assessment by category and severity

⚠️Important Warnings

  • No human clinical trials have been published for 5-Amino-1MQ
  • All preclinical studies used subcutaneous injection, not oral administration
  • Oral bioavailability is unknown despite availability of oral capsule products
  • Long-term safety of NNMT inhibition in humans has not been evaluated
  • Product quality and purity are not regulated by pharmaceutical authorities
  • Animal dose-response data cannot be directly translated to human dosing
  • Effects on methylation balance, cancer risk, and reproductive health are unknown
  • No formal drug interaction studies have been conducted

Legal Status by Country

CountryStatusNotes
United StatesSold as a research chemical. Not FDA-approved for any indication. Not classified as a dietary supplement by FDA. Regulatory status is ambiguous and may be subject to enforcement action.-
InternationalRegulatory status varies by jurisdiction. Generally available as a research chemical in countries without specific restrictions on novel small molecules.-
Legal status map for 5-Amino-1MQ
Geographic overview of regulatory status

Community Risk Discussions

See how the community discusses and manages these risks in practice.

Based on 75+ community reports

View community protocols

Critical Safety Information#

PRECLINICAL RESEARCH COMPOUND ONLY -- 5-Amino-1MQ has zero published human clinical trial data. It has not been evaluated by any regulatory agency for safety or efficacy in humans. The risks described below include both established preclinical observations and theoretical concerns based on the compound's mechanism of action. The actual risk profile in humans is unknown.

Risk Categories#

Risk 1: Complete Absence of Human Data#

This is the overriding risk consideration for 5-Amino-1MQ. Despite being commercially available and widely discussed in biohacking communities, the compound has:

  • Zero published human clinical trials
  • No human pharmacokinetic data (absorption, distribution, metabolism, excretion)
  • No human safety data (toxicology, adverse events, organ effects)
  • No human dose-response data (therapeutic window, maximum tolerated dose)
  • No human efficacy data for any claimed benefit

Many compounds that show dramatic benefits in mouse models fail completely in human trials, either because of lack of efficacy or unacceptable toxicity. The history of drug development shows that approximately 90% of compounds entering clinical trials fail to reach approval. 5-Amino-1MQ has not even entered clinical trials.

Risk 2: Route of Administration Mismatch#

All published in vivo studies used subcutaneous injection in mice. Most commercial products are oral capsules. This creates significant uncertainty:

  • Oral bioavailability may be substantially lower than injectable bioavailability
  • First-pass metabolism through the liver could degrade or alter the compound before it reaches target tissues
  • The effective dose delivered by oral capsules is unknown
  • Gastrointestinal effects of oral 5-Amino-1MQ have not been studied

Risk 3: Unknown Long-term Consequences of NNMT Inhibition#

NNMT is not an isolated enzyme -- it sits at a metabolic crossroads:

  • Methylation homeostasis: NNMT consumes SAM. Blocking NNMT increases SAM availability, potentially affecting genome-wide methylation patterns over time
  • Cancer biology: NNMT is overexpressed in some cancers (may be tumor-promoting) but may serve protective roles in other contexts. Long-term inhibition effects on cancer risk are unpredictable
  • Polyamine metabolism: NNMT influences polyamine pathways that affect cell growth and differentiation
  • One-carbon metabolism: Through its SAM consumption, NNMT connects to folate and one-carbon metabolism -- pathways critical for DNA synthesis and repair

Risk 4: Product Quality Concerns#

As a research chemical:

  • No GMP (Good Manufacturing Practice) requirements apply
  • Purity, identity, and potency testing varies by supplier
  • Contamination with synthesis byproducts, solvents, or other chemicals is possible
  • No batch-to-batch consistency requirements exist
  • The iodide salt form commonly sold has different properties than the free base studied in some research

5-Amino-1MQ occupies an ambiguous regulatory space in most jurisdictions:

  • United States: Sold as a "research chemical" by various suppliers. Not FDA-approved. Not formally classified as a dietary supplement (it is a synthetic small molecule, not a vitamin, mineral, herb, or amino acid). Its sale for human consumption may violate FDA regulations, though enforcement has been limited
  • International: Regulatory status varies. Some countries may classify it differently based on local pharmaceutical and supplement regulations

Warnings#

  1. Do not substitute 5-Amino-1MQ for evidence-based medical treatments for obesity, diabetes, muscle wasting, or any other condition
  2. Inform your healthcare provider if you are using 5-Amino-1MQ, as drug interactions are unstudied
  3. Do not use during pregnancy or lactation -- no reproductive toxicity data exists
  4. Do not use in combination with other NAD+ modulators without understanding that combined effects are unstudied
  5. Be skeptical of marketing claims that extrapolate mouse data to human benefits -- this is scientifically unsupported
  6. Source carefully if choosing to use this compound -- quality varies significantly between suppliers

Explore Further

⚠️

Medical Disclaimer

This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.